Home Latest Articles
Latest Articles
  • Wenxuan ZHANG, Nan LI, Shouquan QIN, Xiang WANG, Wei YAN
    World Clinical Drug. 2023, 44(12): 1316-1321.
    Objective

    To compare the efficacy of mesalazine and salazepyridine in the treatment of children with mild to moderate ulcerative colitis (UC).

    Methods

    A total of 80 children with mild to moderate UC admitted to our hospital from April 2021 to February 2023 were selected and divided into control group and observation group by simple sorting, with 40 cases in each group. The control group received salazepyridine treatment, and the observation group received mesalazine treatment, the course of treatment was 2 months. The clinical efficacy and the changes of intestinal flora, serum D-lactic acid (LAC), perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA), the levels of diamine oxidase (DAO), endotoxins (ET), interleukin (IL)-1β, IL-6 and IL-23 before and after treatment were compared between the two groups, and adverse reactions during treatment and disease recurrence at 12 months of follow-up were recorded.

    Results

    After treatment, the clinical effect of observation group was better than that of control group (P<0.05). Serum levels of D-LAC, P-ANCA, DAO, ET, IL-1β, IL-6 and IL-23 in observation group were lower than those in control group (P<0.05). Enterococcus, Saccharomycetes and Enterobacter were lower than those in control group (P<0.05), Lactobacillus, Bifidobacterium and Bacteroides were higher than those in control group (P<0.05). The number of adverse reactions in control group was higher than that in observation group, but there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). After 12 months of follow-up, there was no significant difference in UC recurrence between the two groups (P>0.05).

    Conclusion

    Both mesalazine and salazepyridine can be used in the treatment of children with mild to moderate UC. Compared with salazepyridine, mesalazine has more advantages in efficacy, reducing serum D-LAC and p-ANCA expression, regulating intestinal flora, inhibiting inflammatory response, and improving intestinal barrier function, with better safety.

  • Yuhong JI, Haiying TENG, Yang WANG
    World Clinical Drug. 2023, 44(12): 1322-1326.
    Objective

    To explore the effects of Nao An dropping pill combined with butylphthalein on serum β2-microglobulin (MG) and homocysteine (HCY) and recombinant S100 calcium binding protein β (S100β) levels in the central nervous system in patients with acute ischemic stroke (AIS).

    Methods

    199 AIS patients treated in our hospital from January 2020 to June 2022 were selected and divided into experimental group (butylphthalein+Nao An dropping pill, n=100) and control group (butylphthalein, n=99) by random number table method. The clinical efficacy, serum β2-MG, HCY, S100β, national institute of health stroke scale (NIHSS), mini mental status examination (MMSE) and the incidence of complications were compared between the two groups.

    Results

    After treatment, the total effective rate of experimental group was higher than that of control group (92.00% vs 74.75%), and the difference was statistically significant (P<0.05). Serum β2-MG, HCY and S100β levels in the two groups were lower than before, and experimental group was lower than control group (P<0.05). NHISS scores in both groups were lower than before, and the experimental group was lower than the control group (P<0.05). MMSE score levels were higher than before, and experimental group was higher than control group (P<0.05). The incidence of adverse reactions in experimental group was lower than that in control group (3.00% vs 5.05%), but the difference was not statistically significant (P>0.05).

    Conclusion

    Nao An dropping pill combined with butylphthalein has a good effect on AIS, which may be related to the improvement of β2-MG, HCY and S100β levels.

  • Honglin HUANG, Jinfan LI, Binyan XIE
    World Clinical Drug. 2023, 44(12): 1327-1329.
  • Jiachen YIN, Yuan XU, Yanzhe YU, Congling CHEN, Xuansheng DING, Jingping ZHANG
    World Clinical Drug. 2023, 44(12): 1330-1334.

    Target drugs for pulmonary arterial hypertension (PAH) have alleviated the clinical symptoms and improved exercise tolerance, accordingly significantly improved the prognosis of PAH patients since launched into the market. Presently most targeted drugs research focused on PAH. For pulmonary hypertension associated with lung diseases and/or hypoxia, and pulmonary hypertension associated with pulmonary artery obstructions, the clinical treatment evidence of PAH targeted drugs has increased in recent years. Based on this, this article reviewed the progress of PAH targeted drugs on different types of pulmonary hypertension, and provided reference for clinical rational drug use.

  • Arigun, Baolechaolu
    World Clinical Drug. 2023, 44(12): 1335-1338.

    Mongolian medicine Sugmuler-3 decoction is a traditional preparation commonly used in Mongolian medicine to treat insomnia. It has been used in clinic for many years, with definite curative effect and few adverse reactions, and is favored by patients. In this paper, chemical composition, pharmacological activity, quality control and clinical application of Sugemuler-3 decoction were summarized to provide reference for its further research and application in the future.

  • Yinghui YU, Guiliang CHEN
    World Clinical Drug. 2023, 44(12): 1339-1344.

    In recent years, the research and development (R&D) of gene therapy has been increasingly highlighted, particularly in the field of rare diseases. As of August 4, 2023, a total of 10 rare disease gene therapy drugs have been approved for market in the world. There are 170 drugs in clinical and registration phases overseas, 46 drugs in clinical stages in China, and most of which are in early clinical phases. The indications covered by gene therapy drugs developed overseas are broader, while drugs developed locally in China have relatively concentrated indications. Biotech companies are the primary R&D enterprises of gene therapy for rare diseases, and many large MNC companies have entered this field through collaboration and acquisition. Currently, there are almost no large and medium-sized companies in China engaged in the R&D of gene therapy for rare diseases. With the development of innovative gene therapy-related technologies and support from relevant regulations, gene therapy will attract increasing attention from Chinese companies in the future. This article analyzed the gene therapy drugs that were currently approved and under development in the world for treating rare diseases to understand the R&D status of gene therapy for rare diseases drugs in China and abroad.

  • Yan YAO, Wei MA
    World Clinical Drug. 2023, 44(12): 1345-1350.
    Objective

    By analyzing the utilization of anesthesia drugs in sample hospitals in Shanghai in recent three years, the development status and trend of anesthesia drugs was understood, so as to provide reference for clinical rational drug use.

    Methods

    The clinical sampling data of anesthesia drugs in sample hospitals in Shanghai from 2020 to 2022 were collected from the Hospital Prescription Analysis System database of China National Pharmaceutical Industry Information Center to analyze the clinical application of anesthesia drugs in the recent three years.

    Results

    Under the influence of centralized drug quantity purchase policy, the price of some non-controlled anesthetics decreased, and the overall anesthesia drugs showed a downward trend, especially in outpatient and emergency departments. The compound growth rate of outpatient and emergency prescriptions in tertiary hospitals and secondary hospitals was -11.89% and -26.63%, respectively. The average cost of medical institutions at all levels decreased to different degrees, and the average compound growth rate of outpatient and emergency costs in tertiary hospitals and secondary hospitals was -20.57% and -27.16%, respectively. Due to the controllability, accuracy and convenience of inhalation anesthetics, the clinical application is expanded and the growth is good. In recent years, the increase of approved drugs and the advent of domestic class I of innovative drugs and product update iteration have increased the clinical selectivity of anesthetics. Clinical use of drugs alone is still the majority and the number of prescriptions accounted for 80.65%.

    Conclusions

    The anesthetics control measures of Shanghai sample hospitals are active and effective, but the multi-drug combination scheme still needs to be actively explored.

  • Shan YE, Yuehua BAO
    World Clinical Drug. 2023, 44(12): 1351-1355.

    The listing and commercial success of belumosudil, the Rho associated coiled-coil-containing protein kinase (ROCK)2 inhibitor, means that ROCK2 target has withstood both clinical trials and test of market. Such targets that have been clinically tested and have good market prospects are usually recognized and followed by domestic innovative drug companies. However, there are few domestic innovative researchers of ROCK2 targets. This paper analyzed this abnormal phenomenon, it was believed that the incomplete patent layout of belumosudil in China was an important reason for the lack of follow-up by domestic innovative pharmaceutical companies. It was also concluded that the patent layout played an important role in the research and development of innovative drugs.

  • Wei LIU, Yuting CAO, Lu ZHAO, Jia LIU, Huan LIU
    World Clinical Drug. 2023, 44(11): 1133-1138.

    Sjögren's syndrome (SS) is an autoimmune disease involving exocrine glands of the whole body. It is characterized by the infiltration of lymphocytes into exocrine glands such as salivary glands and lacrimal glands, resulting in insufficient secretion of the glands. The clinical manifestations are mainly dry mouth and dry eyes, and can also invade the respiratory system and digestive system, thus affecting the quality of life of patients and even life-threatening. The pathogenesis of SS is not yet clear. At present, symptomatic treatment is the main treatment. This article reviewed related drugs in recent years, aiming to provide some reference for clinical practice.

  • Lu ZHAO, Yuting CAO, Wei LIU, Huan LIU
    World Clinical Drug. 2023, 44(11): 1139-1143.

    Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by multiple joint destruction, and in severe cases, there may be irreversible joint destruction and even systemic organ involvement. The therapeutic targets of RA have been constantly explored and updated. This article reviewed the new progress of biologics and targeted drugs for RA, to provide certain reference for clinical drug use.

News